Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.03 is in line with its 3-year average of 0.03, around the middle of its 3-year range (-0.10–0.12).
As of the fiscal period ended Tuesday, June 30, 2026. 66.57% below its 12-month average of 0.08.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.03.
DEBT TO EQUITY RATIO
0.03
DEBT TO EQUITY RATIO AVG TTM
0.08
DEBT TO EQUITY RATIO AVG 3Y
0.03
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-66.57%
CURRENT VS 3Y AVG
-2.58%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 474 covered companies
CURRENT VS SECTOR MEDIAN
-79.76%
vs the sector median at left
Artiva Biotherapeutics, Inc.
Market Cap
$341.86M
Debt to Equity Ratio
0.03
TTM Avg
0.08
3Y Avg
0.03
5Y Avg
N/A
Market Cap
$336.71M
Debt to Equity Ratio
0.12
TTM Avg
0.17
3Y Avg
0.10
5Y Avg
0.07
Market Cap
$344.13M
Debt to Equity Ratio
5.93
TTM Avg
1.11
3Y Avg
0.80
5Y Avg
2.27
Market Cap
$329.60M
Debt to Equity Ratio
0.23
TTM Avg
0.27
3Y Avg
0.28
5Y Avg
0.22
Market Cap
$361.64M
Debt to Equity Ratio
N/A
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$363.70M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.11
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $341.86M | 0.03 | 0.08 | 0.03 | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $336.71M | 0.12 | 0.17 | 0.10 | 0.07 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $344.13M | 5.93 | 1.11 | 0.80 | 2.27 |
| Embecta Corp. (EMBC)vs › | $345.29M | N/A | 0.01 | 0.00 | 0.00 |
| C4 Therapeutics, Inc. (CCCC)vs › | $329.60M | 0.23 | 0.27 | 0.28 | 0.22 |
| Agenus Inc. (AGEN)vs › | $352.29M | N/A | 1.69 | 1.69 | 1.69 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | 0.00 | 0.00 | 0.00 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $363.70M | 0.00 | 0.00 | 0.00 | 0.11 |
| CapsoVision, Inc. (CV)vs › | $323.01M | 0.05 | 0.07 | 0.07 | 0.07 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $365.95M | 0.55 | 2.43 | 1.26 | 0.85 |
Debt/Equity
0.03
Current Ratio
24.16
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.03 |
| 2026-03-31 | 0.12 |
| 2025-12-31 | 0.10 |
| 2025-09-30 | 0.09 |
| 2025-06-30 | 0.09 |
| 2025-03-31 | 0.08 |
| 2024-12-31 | 0.08 |
| 2024-09-30 | 0.07 |
| 2024-06-30 | -0.08 |
| 2024-03-31 | -0.09 |
| 2023-12-31 | -0.10 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
